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Objectives: Phase I (PhI): assess the safety of Polyphenon E in people with multiple sclerosis (MS) and determine
the futility of Polyphenon E as a neuroprotective agent. Correlate plasma levels of EGCG with neuroprotective
effects.
Phase II (PhII): Further assess safety and conﬁrm the neuroprotective effects of Polyphenon E.
Design: PhI: single group futility study. PhII: parallel group randomized double-blind placebo-controlled study.
Participants: Recruitment area (both studies): LSU MS Center, New Orleans, LA and general public from
surrounding areas.
Inclusion criteria (both studies): 1) MS per 2005 McDonald criteria; 2) relapsing remitting or secondary
progressive MS; 3) stable for six months prior to enrollment on either no therapy or glatiramer acetate (GA)
for the PhI study and on either on GA or Interferon β for the PhII study.
Exclusion criteria (both studies): 1) complete bone marrow ablation or alentuzumab use at any time;
2) mitoxantrone, cyclophosphamide, natalizumab or ﬁngolimod use in the prior nine months; 3) liver problems
or signiﬁcant medical problems.
Interventions: PhI: Polyphenon E, a green tea extract containing 50% of the antioxidant Epigallocatechin-gallate
(EGCG), two capsules twice daily (200 mg of EGCG per capsule; total daily dose 800 mg) for six months.
PhII: Polyphenon E or matching placebo capsules, same dose for one year. Only the research pharmacist knew
treatment assignment and she randomized participants (one-to-one, stratiﬁed by GA or Interferon β, blocks of
4 or 6). Outcome evaluators did not discuss side effects with participants.
Outcomemeasures: PhI: 1) adverse events (AE); 2) futility: decrease inN-acetyl aspartate (NAA) from baseline to
six months of 10% or more; 3) association between EGCG plasma levels and change in NAA.
PhII: 1) AEs; 2) difference in the rate of change of NAA-levels over twelvemonths.Wemeasured NAA using a point
resolvedmagnetic resonance spectroscopic imaging sequence (TE30/TR2000) on a 10 cm× 10 cm× 1 cm volume
of interest (VOI) located just superior to the lateral ventricles. The ﬁeld of view was 16 × 16 resulting in 1 cm3
voxels. We quantiﬁed NAA and creatine/phosphocreatine (Cr) levels using LCModel for post-processing.
Results: PhI: Ten participants enrolled and completed all assessments with no serious AEs. One discontinued
therapy due to grade (G) I abnormal liver function tests (LFTs). We included all participants in the analysis. NAA
adjusted for creatine increased by 10% [95% CI(3.4%,16.2%), p b 0.01] rejecting the futility endpoint.
PhII: Thirteen participants enrolled and twelve started treatment. The DSMB stopped the study because 5/7
participants on Polyphenon E had abnormal LFTs (G I, and 1 G III). Median time to onset of abnormal LFTs was
20 weeks [Inter-Quartile Range (IQR) (10,23)]. Only two participants completed the six-month visit, so we
could not analyze the NAA levels.
PhI participants took capsules from lot 189I1107 while 6/7 PhII participants took capsules from a new loty, 1542 Tulane Ave, New Orleans, LA 70112, United States.
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47J. Lovera et al. / Journal of the Neurological Sciences 358 (2015) 46–52(L0206306). Both lots had similar levels of EGCG but differed in the levels of minor catechins. There were no
signiﬁcant differences between the lots on participants' median free EGCG plasma levels at either 3 h or 8 h as
well as conjugated EGCG levels at 3 h (all p N 0.4, Wilcoxon exact test).
Free EGCG levels at 8 h correlated with changes in NAA adjusted bywater content. A 1 ng/ml higher EGCG plasma
concentration correlatedwith a 0.9% increase in NAA[95% CI(0.5%,1.4%), visit*level interaction F= 14.4, p b 0.001].
However, EGCG plasma concentrations did not correlatewith NAA adjusted by creatine (1 ng/ml higher EGCGwas
associatedwith 0.02%,[95% CI(−0.27%,0.3%) change inNAA, p N 0.5]). Therewas a trend towards an increase in cre-
atine levels (referenced to water content) from baseline to exit (1 5% increase, [95% CI(−6%,17%), p = 0.4]). The
free EGCG levels at 8 hours correlated signiﬁcantly with change in creatine levels (1 ng/ml higher EGCG level at
8 hwas associatedwith a 1.1% increase in creatine [95% CI(0.6%,1.6%)]). Thus it is possible that the discrepancy be-
tween the correlation of the EGCG 8 h levels with NAA changes referenced to water and the 8 h EGCG levels with
NAA changes referenced to creatine was due to a change in creatine among the subjects with higher EGCG levels.
Conjugated 3 h and 8 h levels and free 3 h levels did not correlate with NAA changes (all p N0.5).
Conclusions/classiﬁcation of evidence:Class III evidence: Polyphenon E at a dose of 400mgof EGCG twice a day is not
futile at increasing brain NAA levels. Class I evidence: some lots of Polyphenon E have a high risk of hepatotoxicity.
Funding: National Center for Complementary and Alternative Medicine K23AT004433, National Multiple Sclerosis
Society RG4816-A-1 and National Institute of General Medical Sciences 1 U54 GM104940. Mitsui Norin provided
Polyphenon E and placebo and their representative reviewed the manuscript prior to publication. Mitsui Norin
was not involved in other aspects of the study. The decision to submit the manuscript remained with the
investigators.
Registration: NCT00836719 and NCT01451723.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Polyphenon E (Mitsui Norin Co., Ltd; Shizuoka, Japan) is an extract
from leaves of green tea (Camellia sinensis). Themain active component
in Polyphenon E is Epigallocatechin-gallate (EGCG), an antioxidant that
accumulateswithin themitochondria of neurons and decreases apopto-
sis of neurons undergoing oxidative stress [1]. In mice with experimen-
tal autoimmune encephalomyelitis (EAE), mitochondrial dysfunction
leads to axonal injury that can be reversible [2]. For people with
multiple sclerosis (MS), axonal injury is a major determining factor of
disability. EGCG effectively treats EAE in SJL/Jmice [3,4]. The EAE animal
data and the in vitro neuroprotective effects of EGCG led us to hypothe-
size that Polyphenon E may be neuroprotective in MS.
The primary objectives of the pilot studywere: 1) to assess the safety
of Polyphenon E in people with MS, 2) to perform a futility assessment
of the ability of Polyphenon E to be neuroprotective based on its effects
on brain levels ofN-acetyl aspartate (NAA) and 3) correlate the changes
in NAA with plasma levels of EGCG.
NAA is made almost exclusively in neurons [5] and its synthesis is
closely coupled with energy production by mitochondria [5,6]. NAA is
present in oligodendrocyte 2A progenitors mainly during development
[7]. However, in the adult brain, NAA is a speciﬁc marker of neuronal
and axonal pathology [8]. NAA is degraded by oligodendrocytes, but
even in conditions of oligodendrocyte loss where degradation of NAA
could be impaired, NAA does not increase [9]. Thus, NAA levels
measured non-invasively using proton magnetic resonance spectrosco-
py (MRS) can indicate neuronal metabolic health and may be a good
outcome measure when testing potential neuroprotective compounds
[10]. Our pilot study was limited to assessing futility comparing our
data with a similar study done by Khan et al. [11]. The futility cutoff
was set at a 10% decline in NAA over six months.
Based on the results of the PhI study we conducted a PhII random-
ized controlled trial to conﬁrm the PhI results.
2. Methods
2.1. Standard protocol approvals, registrations, and patient consents
The LSUHSC-New Orleans IRB approved both trials, which we
registered with ClinicalTrials.gov (NCT00836719 and NCT01451723).
The protocols are available at http://goo.gl/aOh5ja and http://goo.gl/
xaAAVb. All participants signed the informed consent.2.2. Participants
2.2.1. Inclusion criteria
For both the PhI and PhII studies, we recruited participants ages 18–
60 with MS per the 2005 McDonald criteria (either relapsing remitting
or secondary progressive) [12,13] and an Expanded Disability Status
Scale (EDSS) [14] score ≤ 7.0. For the PhI study, participants had to
have been stable for at least six months prior to starting the study on
either GA or no disease-modifying therapy (Fig. 1). For the PhII, partic-
ipants had to have been stable on either GA or interferon β-1a or 1b.
Participants had to have normal leukocyte, neutrophil, and platelet
counts as well as normal creatinine and liver function tests. We
screened all participants for hepatitis.Womenwith childbearing poten-
tial had to agree to reliable contraception. Participants agreed to refrain
from drinking green tea or taking green tea supplements and to drink at
most only one cup of black tea or two cups of coffee a day.
2.2.2. Exclusion criteria
Participants that had received second-line therapies such as
mitoxantrone, cyclophosphamide, T-cell vaccination, natalizumab, or
(for the PhII study) ﬁngolimod in the prior nine months were ineligible
for the study. Dymethyl-fumarate was not available at the time of the
study. We excluded participants who had ever received bone marrow
radiation or alentuzumab.
Participants could not have consumed green tea or green tea extracts
in the thirty days prior to start of the study. They could not have history of
liver or kidney diseases, an active clinically relevant illness or predisposi-
tion to gastrointestinal bleeding. We did not allow participation in other
studies using investigational agents sixmonths prior to the start or during
our studies. Participants allergic to compounds in the Polyphenon E
capsules or to gadolinium based contrast agents could not participate.
All female participants of childbearing potential completed a screen-
ing pregnancy test; we excluded pregnant women from the study.
2.3. Intervention
The National Cancer Institute (NCI), Division of Cancer Prevention
produced, under contract with Mitsui Norin, the lot of Polyphenon E
capsules taken by the participants in our PhI study (lot 189I1107).
Three subjects in the PhII study also took capsules from lot 189I1107
with one taking capsules only from this lot. Catalent (formerly Aptuit)
produced the Polyphenon E (lot L0206306) and Placebo capsules used
Fig. 1. CONSORT ﬂow-chart PhI study.
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Polyphenon E capsules, each containing 200 mg of EGCG, twice daily
with meals (total dose of EGCG 800 mg/day) for six months. PhII
participants took two Polyphenon E capsules, each containing 200 mg
of EGCG, twice daily with meals (total dose of EGCG 800 mg/day), or
matching placebo capsules for a year.
We selected the dose of 400 mg twice a day because healthy
volunteers in previous studies tolerated this dose for a month well
[15]. Single daily doses of 800 mg are also well tolerated [15] while
single doses of 1200 mg cause nausea in 70% of participants when
given without food and in 20% when given with food [16].
Although Polyphenon E was safe in beagle dogs and rats when
given with food, beagle dogs when given Polyphenon E without
food had high mortality rates [17]. Because of the toxicities seen in
dogs, at the time we initiated our study, the FDA would not allow a
study lasting more than a month with a dose higher than 800 mg a
day given with food.
2.4. Study design
The PhI study was an open-label, six-month study. Study physicians
performed cognitive, EDSS, andMultiple Sclerosis Functional Composite
(MSFC) assessments at baseline and exit. The participants had MR
spectroscopy at baseline and exit to measure NAA.
The PhII study was a randomized double-blind placebo-controlled
study. The research pharmacist randomized participants to Polyphenon
E or placebo. She was the only person aware of treatment assignments.
There were two strata for the randomization: 1) treatmentwith GA and
2) treatment with interferon β. The randomization sequence used
randomly alternating blocks of four and six. The target sample size
was forty-eight participants per arm. NAA levels were to be measured
at baseline, six and twelve months. A trained research assistant (RA)administered EDSS and MSFC assessments at baseline and exit. We
instructed participants not to discuss adverse events with the
evaluating RA.
2.5. Adverse events
In both studies, we provided a calendar at each monthly visit so
participants could record the onset and termination of adverse events.
The study nurse reviewed the calendars and recorded adverse events
on a monthly basis. The study's treating physician further evaluated
AEs as he deemed necessary and determined attribution. He also
determined the category, name and grading according to the Common
Terminology Criteria for AE (v3.0). The study physician also evaluated
and treated MS relapses.
2.6. Plasma levels
One month after beginning the study, participants fasted overnight
and took their morning capsules with a standardized breakfast. After-
wards, participants gave blood to measure free and conjugated plasma
levels of EGCG at three hours (peak) and eight hours (trough). After
adding a preservative solution (20% ascorbic acid and 0.05% Na2EDTA
in 0.4Mphosphate buffer, pH 7.2), we aliquoted and stored the samples
at−80 °C until analysis. Staff at OHSU Bioanalytical/Pharmacokinetics
Shared Resource measured the EGCG levels using liquid chromatogra-
phy with tandem mass spectrometry following a modiﬁcation of
Masukawa's method [18]. OHSU staff processed all PhI samples in a
single run. When investigating the PhII liver toxicity issues, OHSU staff
processed the PhII study samples along with stored aliquots of PhI
samples in a single run in order to compare EGCG plasma levels
between the studies.
2.7. Magnetic resonance imaging and spectroscopy
We used a GE Signa-LX 3.0 T scanner to acquire MRI and MR
spectroscopy data. Using a fast-spoiled-gradient recalled (FSPGR)
sequence, we acquired a T1-weighted anatomical image on an
oblique plane parallel to the anterior–posterior commissural (AC–
PC) line. All sequences following the SPGR used the same plane as
the SPGR. First we obtained a GE Proton Brain Exam using a point
resolved spectroscopy (PROBE-P) magnetic resonance spectroscopic
imaging (MRSI; TE30/TR2000) sequence to select an approximately
10 cm × 10 cm × 1 cm volume of interest (VOI) located just superior
to the lateral ventricles. The ﬁeld of view for the MRSI acquisition
was (16 cm)2 with a 162 matrix to provide isotropic spectroscopy
voxels (10 mm)3. After the MRSI, we acquired proton density (PD);
T2-weighted fast spin echo (FSET2) and T2-weighted ﬂuid-
attenuated-inversion-recovery (FLAIR) scans.
2.8. Post-imaging analysis
We quantiﬁed NAA and creatine/phosphocreatine (Cr) levels using
LCModel (http://s-provencher.com/pages/lcmodel.shtml). Using the
FSL package (http://www.fmrib.ox.ac.uk/fsl), allMRI images underwent
radiofrequency ﬁeld bias correction and registration to the FSPGR space.
We created lesion masks manually from the T2 scans and used SIENAX
to segment the brain into gray matter (GM), white matter (WM) and
cerebrospinal ﬂuid (CSF). Using the MRS viewer SIVIC (http://
sourceforge.net/projects/sivic), we mapped the MRS VOI onto the
FSPGR scans and created a mask representing VOI. We co-registered
the baseline and exit FSPGR images to the halfway space between the
two time-points using SIENA [19], and used the correspondingmatrices
to registerMRS VOImasks into the halfway space. In order to use the PD
scan as a reference for water content, we used baseline and exit MRS
VOImasks.We extracted the VOI from the PD scans and then resampled
Table 1
Participant demographics for the PhI and II studies.
PhI PhII PhII
Placebo Polyphenon
E
N 10 13 5 8
Age and gender
Age years median(range) 45 (39–56) 48 (33–59) 49 (40–56) 47.5 (33–59)
Gender female N(%) 9 (90%) 10 (77%) 5 (100%) 5 (62%)
Race
Caucasian N(%) 9 (90%) 13 (100%) 5 (100%) 8 (100%)
African American N(%) 1 (10%)
Ethnicity
Hispanic 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Unknown 1(10%) 0 (0%) 0 (0%) 0 (0%)
Type of MS
RRMS 9 (90%) 13 (100%) 5 (100%) 8 (100%)
SPMS 1 (10%)
MS disability and duration
EDSS median(range) 4 (1–6.5) 2.5 (1–4) 3 (1–4) 2 (1–4)
Disease duration in years
median(range)
14 (3–34) 12 (2–29) 13 (4–29) 9.5 (2–20)
Disease modifying treatment
Glatiramer acetate 7 (70%) 8 (62%) 3 (60%) 5 (63%)
Interferon β 5 (38%) 2 (40%) 3 (27%)
No DMT 3 (30%)
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the MRS voxels (10 mm)3.
2.9. Deﬁnition of futility
Futility was deﬁned as 95% one-sided conﬁdence that Polyphenon E
treatment could not increase NAA by at least 5% from baseline to 6-
month follow-up; based on our sample size this level of conﬁdence
would be achieved if NAA declined by 10%.
2.10. Statistical analyses
We included only voxels with less than 30% standard deviation
error in NAA and Cr determined from the Cramer-Rao bounds in
LCModel. The median number of usable voxels per participant/
time-point was 35 [IQR:17–40, Max:70]. The average composition
of the spectroscopy region was (31% gray, 52% white, 11% CSF and
0.06% lesions) with a small, not statistically signiﬁcant difference
from baseline and exit (+0.4% for gray, −1.7% white, +0.2% CSF
and −0.5% lesions; p N 0.6 for all differences); there were no
signiﬁcant differences in the composition between the included
and excluded voxels (differences included–excluded: 1% gray,
−0.6% white, 0.9% lesion, 0.6% CSF; p N 0.2 all differences). To
account for the correlation between voxels we used a mixed model
(proc mixed SAS 9-2, Cary, NC) with an anisotropic power spatial co-
variance matrix with terms for time and the voxel coordinates in the
halfway space. To calculate the degrees of freedom, we used
Kenward Rogers' approximation. The model's dependent variable
was NAA, and the main effect was visit. The covariates were percent
of GM, WM, CSF and lesions in the voxel. To reference NAA to Cr,
LCModel's estimate of Cr was included as a covariate; similarly, to
reference to the water content the resampled PD was included.
NAA and Cr were log transformed so the model would be in a
multiplicative scale. The analyses were intention to treat.
3. Results
3.1. PhI
Recruitment for the PhI study started 9/2009 and ended 4/2010.
Follow-up completed on 11/2010. We screened 11 participants with
one screen failure due to abnormal LFTs. Table 1 shows the participant
demographics.
All participants completed the study. One discontinued therapy
because of grade 1 (b2× normal) elevation of liver enzymes but still
completed the exit assessment.
Treatment with EGCG resulted in an NAA increase of 10% [95%,
CI(3%–16%), p b 0.01] when referenced to Cr signal intensity and 13%
[95%, CI(1%–23%) p b 0.01] when referenced towater contentmeasured
from the PD image. No signiﬁcant changes in brain atrophy, EDSS,MSFC,
or cognitive measures occurred. There were no signiﬁcant correlations
between conjugated or free plasma levels at either 3 h or 8 h and change
in NAA levels adjusted for creatine. The free plasma levels of EGCG at 8 h
correlated to the changes over six months in NAA levels adjusted by
water content; an increase in 1 ng/ml in free EGCG levelswas associated
with in a 0.9% [95% CI(0.5%–1.4%), p b 0.01] increase in NAA between
baseline and exit.
3.2. PhII
Table 1 also shows the demographics for the PhII study and Fig. 2 the
CONSORT ﬂow-chart.
Enrollment started on 7/15/2011. The MRS data and other clinical
outcomes were uninterpretable because only two participants in the
treatment arm completed the six-month follow up point.3.3. Adverse events
3.3.1. Serious adverse events
There were no serious adverse events (SAE) in the PhI study. There
were two serious adverse events in the PhII study: one participant on
placebo had a basal cell carcinoma and one participant on active
treatment had AST and ALT elevated 15 times above normal Grade III
and elevated bilirubin (total 1.3 mg/dl and indirect 0.38 mg/dl). The
concomitant elevation of transaminases and bilirubin made this a seri-
ous adverse event. The participant's liver function tests (LFTs) normal-
ized two months after discontinuing treatment.3.3.2. Decision to terminate the PhII study
Thehigher frequency of abnormal LFTs in the PhII study compared to
the PhI study and the abnormal LFT SAE, led the DSMB to request an un-
blinded analysis from theDSMB's statistician on 9/12/2012. The analysis
included the six participants on active treatment and ﬁve participants
on placebo who had at least one follow-up visit. Five out of six partici-
pants treatedwith Polyphenon E (Grade I:4 participants, Grade III:1 par-
ticipant) and one out of ﬁve participants treated with placebo had
abnormal LFTs (Fisher's exact test p = 0.07, exact conditional mid-p-
value p b 0.05). Furthermore, the participant on the placebo arm only
had a single episode of isolated elevated bilirubin; disregarding this
event the p-value for the Fisher's exact test was less than 0.05. The LFT
elevations did not seem related to concurrent use of interferon
treatment as 4/4 participants on glatiramer acetate and 1/2 participants
on interferon had abnormal LFTs (Fisher's exact test= 0.16). The DSMB
requested that all participants stop treatment on 9/26/2012 and
requested a comparison of the results of the two studies. Two out of
ten PhI participants vs. 5/6 PhII participants treated with Polyphenon
E had liver enzyme elevations. One of the PhI participants had a history
of fatty liver that she had forgotten to discuss on enrollment; excluding
this participant 1/9 PhI vs. 5/7 PhII participants had liver enzyme
elevations (Fisher's exact test = 0.01). The difference in incidence of
abnormal LFTs between the PhI and II studies made us review the
product lots. All ten PhI participants received Polyphenon E from lot
189I1107. Of the PhII participants, one participant received product
Fig. 2. Consort ﬂow-chart phase II study.
Table 2
Pharmacokinetic data.
Time Study N EGCG Median [IQR] ng/ml p value1
3 h PhI 10 Free 160 [132–267] 0.2
PhII 6 Free 102 [86–179]
PhI 10 Conjugated 205 [181–483] 0.7
PhII 6 Conjugated 325 [156–472]
8 h PhI 10 Free 19 [10–53] 0.6
PhII 6 Free 40 [34–44]
PhI 10 Conjugated 78 [43–116] 0.03
PhII 6 Conjugated 162 [98–254]
[IQR] Interquartile range.
1 Wilcoxon rank sum two-sample test.
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from lot 189I1107 and then changed to lot L0206306. Two out of twelve
participants had abnormal LFTs while using lot 189I1107 and 4/6
participants had abnormal LFTs while using lot L0206306 (p b 0.03
Fisher's exact test). Since there were no alternative lots of Polyphenon
E available, the DSMB and the PI decided to terminate the study.
3.3.3. Other adverse events
Table E1 of the electronic appendix shows a detailed list of adverse
events.
Aside from the elevated LFT's, nausea (6/17 Polyphenon E vs. 1/5
placebo) and abdominal pain (5/17 Polyphenon E vs. 1/5 placebo)
were the most common adverse events.
3.4. Pharmacokinetics
Table 2 shows the pharmacokinetic data. There was a trend towards
lower free 3 h EGCG levels for the PhII study participants vs. the PhI
but none of the comparisons between studies reached statistical
signiﬁcance.
3.5. Quality control
3.5.1. Shipping and storage
Review of the storage records showed stable room temperatures in
the pharmacy locker throughout both phases of the study. We
instructed participants to store the product at room temperature but
we have no documentation of how exactly they stored it. NCI and
Catalent (formerly Aptuit) shipped our study drug inmultiple overnightshipments of 300 to 600 capsules. Thus, no individual shipment
problem could account for the problems with the product.
3.5.2. Quality control
We repeated the quality control analyses on a sample from the lot
used in the PhI study (lot 189I1107) obtained from the NCI repository,
on a sample from lot L0206306 from the Catalent (formerly Aptuit)
repository, and on a sample from lot L0206306 that remained stored
at our researchpharmacy. Aptuit analyzed the samples using a validated
reversed phase HPLC with 280 nm UV light detection method. The
validation only included the EGCG content. The HPLC results also
included percent areas referenced to EGCG for minor catechins peaks
identiﬁed by their expected relative retention times. However, the
assay only included spiked EGCG standards. Appearance, moisture
content, and levels of EGCG were quite similar for the three sources.
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L0206306 had 95.1%–94.8%, and the sample from lot L0206306 obtained
from the Catalent (formerly Aptuit) repository had 95.8%–96.1%. The
two samples from lot L0206306 had nearly identical contents of minor
catechins; however, Lot 189I1107 had higher levels of Catechin-
galleate and Gallo Catechin-galleate than lot L0206306 and had lower
levels of Epicatechin, Epigallo-catechin and Catechin. The samples
from the three sources released more than 90% of their content by 60
minutes. Table E2 presents details on the results for the quality control
analyses.
4. Discussion
This is the ﬁrst study to evaluate the safety of Polyphenon E in
patients with MS and assess its futility as a neuroprotective treatment.
A futility study does not try to prove efﬁcacy but instead provides a
clear decision rule as to whether a treatment should be studied in a
larger study.
NAA measurement using MRS is a unique tool for assessing
neuroprotection. Neurons with unhealthy mitochondria will produce
less NAA and after receiving a treatment that improves mitochondrial
function neurons should produce more NAA. Polyphenon E contains
EGCG, an antioxidant that mitochondria concentrate and thus EGCG
could protect them from the free radical injury associated with low-
grade inﬂammation in MS. Therefore, Polyphenon E could potentially
restore mitochondrial function resulting in an increase in NAA levels
as the PhI study suggested. NAA increased in the participants in our
PhI study rejecting the futility cutoff. This indicated that Polyphenon E
warranted further investigation in a larger placebo-controlled trial,
which we started.
There were no changes made to the MRI instrument, to either its
hardware or its software, throughout the study so changes in the
scanner were not likely the cause of increased NAA levels. However,
with no control group, we cannot exclude drifts in the instrument as
the cause of the increase in NAA but the normalization to creatine and
to less extent to water content protect against this bias.
Unfortunately, our PhII study terminated prematurely due to the
unexpectedhigh frequency of elevated liver enzymes in the participants
treated with Polyphenon E. The high frequency of elevated liver
enzymes appeared related to the use of a new product lot, which the
majority of PhII participants used. The cause of the difference in toxicity
between the lots remains unclear. The quality control analyses showed
identical concentrations of EGCG between the two lots, as expected
considering that the capsules are standardized by their EGCG content.
Differences in levels of the minor catechins between the lots could
account for the differential toxicity. The quality control analyses
suggested differences between the lots in several minor catechins
relative to the EGCG peak but absolute quantitationwas not performed.
Another contaminant not measured in the quality control analyses
could also be responsible for the toxicity. We did not analyze the
samples for concentrations of the extraction solvents (methanol and
ethyl acetate), but their concentrations were likely very low since
both solvents are highly volatile and the extract is completely dry.
Other trials using the same lot of our PhII study have not experienced
similar difﬁculties related to liver toxicity so it is possible that our
participants had a unique genetic background that made them more
susceptible.
Higher plasmaEGCG levels are achievedwhen Polyphenon E is given
without food [16]; a dose of 800 mg without food is well tolerated but
1200 mg results in frequent nausea [16]. The FDA does not allow any
further human studies with Polyphenon E when given in the fasting
state because of high mortality seen in dogs when given a daily dose
comparable to 1200 mg of Polyphenon E without food [17]. Due to
these results in dogs, at the time of our study initiation, 400 mg twice
a day dose given with food was the highest safe dose that the FDA
would allow for more than a month. However, more recent studiesusing Polyphenon E to treat chronic lymphocytic leukemia have been
able to escalate the doses up to 2000 mg twice a day given with food
[20] with reasonable safety for up to six months (16% discontinuation
due to elevated LFTs and 5% discontinuation due to other causes) [21].
For breast cancer the maximum tolerated dose is estimated to be
600 mg twice a day (b25% participants experiencing dose limiting tox-
icities) [22]. Thus, some people may be able to tolerate the higher doses
used for cancer but the dose we used of 400 mg twice a day is probably
the dose that most participants would be able to consistently tolerate.
Although Polyphenon E appeared promising as a neuroprotective
agent in the PhI study, this effect remains unconﬁrmed. Further studies
with Polyphenon E are unviable as there are no additional lots of the
drug. People with MS should be very cautious about using other green
tea extracts available in the supplement market as the evidence so far
suggests that they may not be safe. At the very least, people using
these supplements should have frequent liver test monitoring. Future
studies may want to focus on pure EGCG products whose composition
may be easier to monitor.Nonstandard Characters Code03B2βSupplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jns.2015.08.006.Acknowledgments
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